NGM Biopharmaceuticals, Inc. (NGM) Tops Q2 EPS by 4c

NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) reported Q2 EPS of ($0.46), $0.04 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $1.42 million versus the consensus estimate of $3.3 million.

For earnings history and earnings-related data on NGM Biopharmaceuticals, Inc. (NGM) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Pan American Silver (PAAS) Misses Q2 EPS by 19c
• Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance